Your browser doesn't support javascript.
loading
Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation.
Marty, Francisco M; Ljungman, Per T; Chemaly, Roy F; Wan, Hong; Teal, Valerie L; Butterton, Joan R; Yeh, Wendy W; Leavitt, Randi Y; Badshah, Cyrus S.
Affiliation
  • Marty FM; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
  • Ljungman PT; Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
  • Chemaly RF; MD Anderson Cancer Center, University of Texas, Houston, Texas.
  • Wan H; Merck & Co., Inc., Kenilworth, New Jersey.
  • Teal VL; Merck & Co., Inc., Kenilworth, New Jersey.
  • Butterton JR; Merck & Co., Inc., Kenilworth, New Jersey.
  • Yeh WW; Merck & Co., Inc., Kenilworth, New Jersey.
  • Leavitt RY; Merck & Co., Inc., Kenilworth, New Jersey.
  • Badshah CS; Merck & Co., Inc., Kenilworth, New Jersey.
Am J Transplant ; 20(6): 1703-1711, 2020 06.
Article in En | MEDLINE | ID: mdl-31883426
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cytomegalovirus Infections / Hematopoietic Stem Cell Transplantation Type of study: Clinical_trials Limits: Adult / Humans Language: En Journal: Am J Transplant Journal subject: TRANSPLANTE Year: 2020 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cytomegalovirus Infections / Hematopoietic Stem Cell Transplantation Type of study: Clinical_trials Limits: Adult / Humans Language: En Journal: Am J Transplant Journal subject: TRANSPLANTE Year: 2020 Type: Article